Stock·NASDAQ·Healthcare
Viking Therapeutics Inc (VKTX)
- Market cap
- $3.17B
- Dividend yield
- None
- Street target
- $95.00median of 21 analysts
- 52-week range
- $23.82 $43.15
VKTX stock forecast today
Where VKTX stands today, and what CleaRank Financial AI makes of it.
VKTX at a glance
Viking Therapeutics Inc (VKTX): Sell, 34/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($31.00 and $32.49).
- Earnings VKTX has not beaten estimates in any of the 5 reports in our data.
- Insiders Insiders sold $23.2M and bought $150K over the last 18 months.
Figures as of October 27, 2026.
CleaRank Financial AI
CleaRank rates Viking Therapeutics Inc (VKTX) Sell, with a model score of 34/100.
The analysts' outlook lifts the score most: 19 of 21 analysts rate it a buy and the median target is 281.7% above the price. Momentum holds it back most: the 14-day RSI of 38.5 is in the bearish zone and the MACD line is negative. The trend is down: VKTX trades 19.70% below its 50-day average of $31.00 and 23.39% below its 200-day average of $32.49. Over the past year the price fell 30.73%.
Only on CleaRank
Figures we compute ourselves from VKTX's own price, earnings and insider-filing history. Tap one to see it in context.
VKTX stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $24.89 is 19.7% below the 50-day simple moving average of $31.00.Price above its 200-day average ›
The price is 23.4% below the 200-day simple moving average of $32.49.50-day average above the 200-day ›
The 50-day average ($31.00) is 4.6% below the 200-day average ($32.49), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 6% of its 52-week range, between $23.82 and $43.15.
VKTX share price
Pick a period: each tab shows how far VKTX has moved over it, to the last close.
Today's trading
Where VKTX sits inside today's range and its 52-week range.
VKTX fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
0/1Beat estimates in most recent reports ›
VKTX beat the EPS estimate in 0 of the 5 reports in our data.
Key statistics
The headline figures for VKTX.
As of October 27, 2026, VKTX trades at $24.89, with a market value of $3.17B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of VKTX's valuation, growth and risks.
Viking Therapeutics Inc (VKTX) cannot be valued on earnings, since its P/E is not meaningful: its earnings per share over the last 12 months are negative. To put its size in context, VKTX has a market capitalisation of $3.2B.
Its return on equity of -88.85% is below the sector median of 7.3%. Debt-to-equity stands at 0.01.
The most recent available report in our data, dated April 29, 2026, showed VKTX earning -$1.37 per share against analysts' estimate of -$0.91. That was a miss, and the stock slipped 0.48% in the first session after the release.
VKTX has not beaten the EPS estimate in any of the 5 reports in our data. Of the 3 reports before the latest, the largest reaction came after the October 22, 2025 report, which missed the estimate by 20.90% while the stock rose 7.96%. Looking ahead, analysts expect EPS of -$4.59 this fiscal year and -$4.34 the year after.
VKTX typically moves 7.99% in a day, and its beta against the S&P 500 is 0.65. The stock is 42.32% below its 52-week high of $43.15, and the downtrend carries risk for as long as the price remains under both moving averages. Insider activity over the last 18 months shows $23.2M in sales against $150K in purchases. Sales can be planned ahead or made to cover taxes on vesting shares, so they carry less weight than buying does.
VKTX against the Healthcare sector
How VKTX compares with the median Healthcare stock CleaRank tracks.
Return vs XLV: Since May 15, 2025, VKTX has lost 9.2% against a gain of 37.3% for XLV.
Performance against XLV
VKTX and the Healthcare sector fund over the same days.
Earnings reality check
Did VKTX beat what analysts expected, and how did the stock react?
Earnings record: VKTX did not beat the analyst estimate in the 5 reports in our data.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Apr 29, 2026after close | -$0.91 | -$1.37 | -50.55% | -0.48% | +3.03% |
| Oct 22, 2025after close | -$0.67 | -$0.81 | -20.90% | +7.96% | +12.09% |
| Jul 23, 2025after close | -$0.44 | -$0.58 | -31.82% | +0.30% | +0.93% |
| Apr 23, 2025after close | -$0.31 | -$0.41 | -32.26% | -0.50% | +11.94% |
| Feb 5, 2025after close | -$0.27 | -$0.32 | -18.52% | -6.09% | -12.48% |
Reports after April 29, 2026 are not yet in our data.
As of October 27, 2026, VKTX has beaten the analyst EPS estimate in 0 of the 5 reports in our data; its most recent report in our data, on April 29, 2026, came in 50.55% below the estimate and the stock moved -0.48% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
VKTX AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 38.5, showing bearish momentum without being oversold.RSI above 50 ›
An RSI of 38.5 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank Financial AI analysis of VKTX
The score, the reasoning behind it, and what could move the price next.
VKTX, which is Viking Therapeutics Inc, changes hands at $24.89 and sits below both of its main averages. The stock is 19.70% below its 50-day average of $31.00 and 23.39% below its 200-day average of $32.49. Within its 52-week range it stands at 6%, which is 4.49% above the 52-week low of $23.82.
On momentum, the 14-day RSI reads 38.5, in the bearish zone, above the oversold line, with the MACD line negative. The recent returns all show a loss, with the price down 26.49% over the past three months, 23.16% over the past six months and 30.73% over the past year. The price rose 2.81% in the last session on volume 28.3% below its average.
New analyst coverage ›
UBS started coverage at Buy on October 15, 2026.
Source: Analyst action, UBS, October 15, 2026Rating reaffirmed ›
Canaccord Genuity kept its Buy rating on October 20, 2026.
Source: Analyst action, Canaccord Genuity, October 20, 2026
Earnings miss ›
The April 29, 2026 report missed the EPS estimate by 50.55%, and the share price fell 0.48% in the first session after it.
Source: Earnings report, April 29, 2026
- Two levels matter most right now: the 20-day EMA at $27.28, which sits above the price, and the 52-week low at $23.82, which sits below it.
- The 14-day RSI reads 38.5, in the bearish zone, with the MACD line negative; readings above 70 or below 30 mark stretched momentum.
- The share price dropped 0.48% in the first session after the April 29, 2026 report. Across the 5 reports in our data, VKTX has beaten estimates 0 times.
VKTX remains in a downtrend while it sits below both its 50-day average of $31.00 and its 200-day average of $32.49. A close back above the 50-day average would be the first sign of repair. Overhead, the 20-day EMA at $27.28 is the first level the price would have to clear.
The next level below the price is the 52-week low of $23.82. With the RSI in the bearish zone, momentum argues against a fast rebound.
Technical indicators
Momentum and trend for VKTX, from its daily closes.
As of October 27, 2026, with VKTX at $24.89, its 14-day RSI is 38.5 (showing bearish momentum without being oversold), its 50-day simple moving average is $31.00 and its 200-day is $32.49.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What VKTX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, VKTX's 1-year correlation of daily returns is +0.30 with S&P 500 (SPY), +0.30 with Nasdaq 100 (QQQ), +0.20 with Bitcoin (BTC) and +0.11 with gold (XAU).
VKTX price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
19 of 21 analysts rate it a buy or strong buy, 2 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $95.00 is 281.7% above the price.More buy ratings than three months ago ›
19 of 21 rate it a buy now, against 18 of 20 three months ago.
VKTX Wall Street View
12-month price targets
The price, $24.89, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 20, 2026 | Canaccord Genuity | Maintains | Buy |
| Oct 15, 2026 | UBS | Initiates | Buy |
| Oct 7, 2026 | Truist Securities | Maintains | Buy |
| Sep 23, 2026 | Truist Securities | Maintains | Buy |
| Aug 11, 2026 | JP Morgan | Maintains | Overweight |
| Jul 30, 2026 | Canaccord Genuity | Maintains | Buy |
As of October 27, 2026, 21 Wall Street analysts cover VKTX: 19 rate it a buy or strong buy, 2 a hold and 0 a sell or strong sell. Their 12-month price targets range from $38.00 to $125.00. The median VKTX price target is $95.00, 281.7% above the price of $24.89.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
VKTX trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
VKTX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Short entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
VKTX moves about 8.0% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much VKTX tends to move, against the market and on its own.
VKTX price history and drawdowns
VKTX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 7.99% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 88.7%, from September 2018 to May 2022, regained by April 2023.Most 1-year holds ended higher ›
53% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $228,349, against $42,376 in the S&P 500 (SPY).
VKTX Drawdowns & Recovery
As of October 27, 2026, VKTX's worst peak-to-trough fall over the last 10 years with dividends reinvested was -88.7% (September 2018 to May 2022); it regained that peak by April 2023, 11 months after the low, and 53% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into VKTX in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: VKTX beat the S&P 500 over this period: $228,349 against $42,376.
A $10,000 investment in VKTX in October 2016 would be worth about $228,349 today with dividends reinvested, compared with about $42,376 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to VKTX, and which have not.
Strongest month, February: an average of +14.19%, up in 6 of 10 years.
Weakest month, August: an average of -1.86%, up in 5 of 10 years.
This month, October: has averaged +10.66%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, VKTX's strongest calendar month has been February (average +14.19%, up in 6 of 10 years) and its weakest August (average -1.86%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
VKTX stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in VKTX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in VKTX today could grow to about $15,541 by 2030 in the base case, with a 90th-percentile outcome near $55,984 and a 10th-percentile outcome around $4,314. Projections are statistical simulations, not guarantees.
VKTX Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $38.68 for VKTX by 2030 in the base case, from $24.89 today (1.6x over 4 years). The 10th-percentile path ends near $10.74. These are outcomes of a Monte Carlo simulation run on VKTX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $14.64 | $27.79 | $52.75 | |
| 2028 | $12.54 | $31.03 | $76.79 | |
| 2029 | $11.42 | $34.64 | $105 | |
| 2030 | $10.74 | $38.68 | $139 |
Method: a lognormal simulation of VKTX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. VKTX is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. How the simulation works
VKTX insider trading
What the people running the company have bought and sold.
VKTX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $150K on the open market and sold $23.2M.
As of October 27, 2026, VKTX insiders reported 14 open-market sales worth $23.2M and 1 open-market purchase worth $150K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jul 31, 2026 | Dorothy Elizabeth Kelly-Gemmell
Director
|
Grant | 6.3K | - |
| Jul 29, 2026 | Brian Lian
Chief Executive Officer
|
Sell | 148.5K | $4.9M |
| Jul 29, 2026 | Gregory S Zante
Chief Financial Officer
|
Sell | 21.2K | $710.1K |
| Jul 29, 2026 | Marianna Mancini
Chief Operating Officer
|
Sell | 18.2K | $609.6K |
| Jul 28, 2026 | Brian Lian
Chief Executive Officer
|
Grant | 221.7K | - |
| Jul 28, 2026 | Marianna Mancini
Chief Operating Officer
|
Grant | 31.7K | - |
| Jul 28, 2026 | Gregory S Zante
Chief Financial Officer
|
Grant | 31.7K | - |
| Mar 10, 2026 | Neil William Aubuchon
Officer
|
Buy | 4.5K | $149.9K |
| Jan 5, 2026 | Brian Lian
Chief Executive Officer
|
Sell | 233.4K | $7.7M |
| Jan 5, 2026 | Marianna Mancini
Chief Operating Officer
|
Sell | 57.7K | $1.9M |
| Jan 5, 2026 | Gregory S Zante
Chief Financial Officer
|
Sell | 57.7K | $1.9M |
| Jan 2, 2026 | Matthew W Foehr
Director
|
Sell | 16.0K | $561.7K |
| Jan 2, 2026 | Matthew W Foehr
Director
|
Option | 16.0K | $53.3K |
| Jan 2, 2026 | Matthew W Foehr
Director
|
Grant | 3.2K | - |
| Jan 2, 2026 | Brian Lian
Chief Executive Officer
|
Grant | 302.5K | - |
| Jan 2, 2026 | Lawson Macartney
Director
|
Grant | 3.2K | - |
| Jan 2, 2026 | Marianna Mancini
Chief Operating Officer
|
Grant | 73.0K | - |
| Jan 2, 2026 | Sarah Kathryn Rouan
Director
|
Grant | 3.2K | - |
| Jan 2, 2026 | Charles A Rowland Jr
Director
|
Grant | 3.2K | - |
| Jan 2, 2026 | J Matthew Singleton
Director
|
Grant | 3.2K | - |
| Jan 2, 2026 | Gregory S Zante
Chief Financial Officer
|
Grant | 73.0K | - |
| Oct 28, 2025 | Brian Lian
Chief Executive Officer
|
Sell | 39.0K | $1.4M |
| Oct 28, 2025 | Marianna Mancini
Chief Operating Officer
|
Sell | 6.2K | $216.5K |
| Oct 28, 2025 | Gregory S Zante
Chief Financial Officer
|
Sell | 6.2K | $216.5K |
| Oct 27, 2025 | Charles A Rowland Jr
Director
|
Sell | 60.0K | $2.1M |
| Oct 27, 2025 | Brian Lian
Chief Executive Officer
|
Grant | 70.1K | - |
| Oct 27, 2025 | Marianna Mancini
Chief Operating Officer
|
Grant | 11.1K | - |
| Oct 27, 2025 | Charles A Rowland Jr
Director
|
Grant | 60.0K | $2.2M |
| Oct 27, 2025 | Charles A Rowland Jr
Director
|
Option | 16.0K | $574.9K |
| Oct 27, 2025 | Gregory S Zante
Chief Financial Officer
|
Grant | 11.1K | - |
| Jul 3, 2025 | Brian Lian
Chief Executive Officer
|
Sell | 26.9K | $747.6K |
| Jul 3, 2025 | Marianna Mancini
Chief Operating Officer
|
Sell | 4.3K | $118.5K |
| Jul 3, 2025 | Gregory S Zante
Chief Financial Officer
|
Sell | 4.3K | $118.4K |
| Jul 2, 2025 | Brian Lian
Chief Executive Officer
|
Grant | 48.3K | - |
| Jul 2, 2025 | Marianna Mancini
Chief Operating Officer
|
Grant | 7.7K | - |
| Jul 2, 2025 | Gregory S Zante
Chief Financial Officer
|
Grant | 7.7K | - |
Source: TwelveData, from SEC Form 4 filings
VKTX stock forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.